Boehringer's Praxbind gets FDA approval as specific reversal agent for Pradaxa

Boehringer Ingelheim Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Praxbind (idarucizumab) as a specific reversal agent for Pradaxa (dabigatran etexilate mesylate).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news